MEK is downstream of the RAS-RAF-MEK-ERK pathway (ERK signaling), which is one of the MAPK pathways, and its aberrant activation associates with various tumorigenic diseases, including NSCLC [39, 40]. Here, MAP2K7 is linked to non-small cell lung carcinoma.